RCAG
RPRX icon

Rehmann Capital Advisory Group’s Royalty Pharma RPRX Stock Holding History

Rehmann Capital Advisory Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,398
Closed -$255K – 682
2025
Q3 		$255K Sell
7,398
-1,358
-16% -$49.2K 0.01% 553
2025
Q2 		$315K Sell
8,756
-8,893
-50% -$295K 0.02% 466
2025
Q1 		$549K Buy
+17,649
New +$559K 0.03% 341

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rehmann Capital Advisory Group's RPRX Position: Q4 2025 in Review

Rehmann Capital Advisory Group sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 7,398 shares — an estimated $255K sold.

Rehmann Capital Advisory Group first reported a position in RPRX in Q1 2025 and held it in 3 quarters. The position peaked at $549K in Q1 2025. 540 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

  • Rehmann Capital Advisory Group reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 7,398 Royalty Pharma shares in Q4 2025, an estimated $255K.
  • Rehmann Capital Advisory Group first reported a position in Royalty Pharma in Q1 2025 and held it in 3 quarters.
  • Rehmann Capital Advisory Group's Royalty Pharma position peaked at $549K in Q1 2025.
  • 540 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on Rehmann Capital Advisory Group's 13F filing for Q4 2025, filed 4 Mar 2026.